







## Symposium: 'What's new since FOXP2: new developments in speech and language neurobiology'

Friday 7 June 2024, Leolin Price Lecture Theatre - University College London GOS Institute of Child Health, 30 Guilford Street, WC1N 1EH (one day in-person only)

Session	Time	Торіс	Speaker	Chair
	8:45 – 9:15am	Registration & coffee/tea on arrival		
FOXP2 and the genetic basis for speech disorders – where it all began and where are we now?	9:15 – 9:30am	Opening	A/Prof. Frederique Liegeois University College London & Prof. Angela Morgan Murdoch Children's Research Institute	A/Prof. Frederique Liegeois
	9:30 – 10:00am	Tracing connections between FOXP genes and speech development	Prof. Simon Fisher Max Planck Institute for Psycholinguistics	
	10:00 – 10:30am	Neurocognitive trajectory of a case with translocation of <i>FOXP2</i>	Prof. Faraneh Vargha-Khadem University College London	
	10:30 – 11:00am	Brain basis of Childhood Apraxia of Speech from FOXP2 to now	A/Prof. Frederique Liegeois University College London	
	11:00 – 11:30am	Coffee break		
Child speech disorder phenotypes in the context of broader neurodevelopment	11:30 – 12:00pm	Monogenic contributions to Childhood Apraxia of Speech - lessons from the clinic	Prof. Angela Morgan (MCRI) & Prof. David Amor University of Melbourne	Prof. Angela Morgan
	12:00 – 12:30pm	Monogenic contributions to speech delay	Dr. Else Eising Max Planck Institute of Psycholinguistics	
	12:30 – 1:00pm	How do rare and common genetic variations lead to human disease? Lessons in epilepsy	Prof. Ingrid Scheffer University of Melbourne	
	1:00 – 2:00pm	Lunch break		

Childhood language disorders	2:00 – 2:30pm 2:30 – 3:00pm 3:00 – 3:30pm	Identifying genes underlying Ianguage disorders Integrated gene and brain mapping of Ianguage abilities Brain basis of developmental language disorders: recent discoveries using advanced MRI methods	Prof. Dianne Newbury Oxford Brookes University Prof. Michelle Luciano University of Edinburgh Prof. Saloni Krishnan University of London	Prof. Ingrid Scheffer
	3.30 – 4:00pm	Coffee break		
	4:00 – 4:30pm	Mouse models of speech disorders – unravelling mechanisms to improve diagnosis and treatment	Prof. Michael Hildebrand University of Melbourne	
discussion	4:30 – 5:00 pm	Genetics and neurobiology of child speech and language disorders - where to next in research and clinical practice? Questions from the audience	Panel members: Prof. Simon Fisher Prof. Michael Hildebrand A/Prof. Frederique Liegeois Prof. Ingrid Scheffer	Prof. Sheena Reilly
	5:00pm	Drinks reception		

SPEAKERS				
	<b>Prof. Angela Morgan</b> is a senior speech pathologist, NHMRC Dame Elizabeth Blackburn Fellow and leads the Speech and Language group at the Murdoch Children's Research Institute in Melbourne, Australia. Angela is also a Dame Kate Campbell Professorial Fellow of the University of Melbourne. Her expertise is in the diagnosis of child speech disorders. She is Director of the Speech Apraxia and Genetics Clinic at the Royal Children's Hospital. Angela leads the Centre of Research Excellence – Translational Centre for Speech Disorders.			
	<b>A/Prof. Frederique Liegeois</b> is a cognitive neuroscientist and head of the Clinical System Neuroscience Section at the University College London (UCL) Great Ormond Street Institute of Child Health, one of the world's leading institutions in paediatric research. Frederique is internationally renowned for her work on the neural bases of inherited and acquired communication disorders. She combines neuropsychological and speech- language phenotyping with advanced brain MRI analyses to unravel potential mechanisms at the root of communication challenges in individuals with rare genetic variations, as well as in young people with more prevalent conditions (e.g. brain injury, preterm birth).			
	<b>Prof. Simon E. Fisher</b> is director of the Max Planck Institute for Psycholinguistics and Professor of Language and Genetics at the Donders Institute for Brain, Cognition and Behaviour, in Nijmegen, the Netherlands. Simon's research focuses on molecular mechanisms involved in human speech and language abilities. His work has an interdisciplinary perspective, integrating data from genetics/genomics, psychology, neuroscience, developmental biology and evolutionary anthropology.			
	<b>Prof. Faraneh Vargha-Khadem</b> is a developmental <u>cognitive neuroscientist</u> and a paediatric clinical neuropsychologist specializing in childhood conditions of genetic and neurological origin. Faraneh was part of the team that identified the <u>FOXP2</u> gene, and wrote highly cited review on the topic. Over the past decades she has published seminal work in the following research areas: (a) Developmental amnesia associated with hippocampal injury; (b) Motor speech and language disorders resulting from mutation of FOXP2 gene; and (c) Reorganisation of cognitive and sensorimotor function in children undergoing epilepsy surgery.			
	<b>Prof. David Amor</b> is an internationally recognised consultant clinical geneticist and clinician scientist with a research focus on human genetic disorders. David is a Galli Chair in Developmental Medicine in the Department of Paediatrics, University of Melbourne, Australia. He is also a Research Group Leader of Neurodisability & Rehabilitation at the Murdoch Children's Research Institute.			

<b>Dr. Else Eising</b> is a post-doctoral researcher in the Language and Genetics Department, Max Planck Institute for Psycholinguistics in Nijmegen, the Netherlands. Her work focuses on the genetics of speech and language-related traits and disorders, with a main focus on stuttering. Else is also involved in various 'gene hunting' projects searching rare variants that cause rare speech disorders, and in genome wide association studies searching common variants associated with language, reading and musicality-related traits.
Laureate Prof. Ingrid Scheffer AO is a physician-scientist whose work as a paediatric neurologist and epileptologist at the University of Melbourne and Florey Institute has led epilepsy genetics research over 25 years. In collaboration with Professor Samuel Berkovic and molecular geneticists, they identified the first epilepsy gene and many genes subsequently. She led the first major International League Against Epilepsy revision of the classification of epilepsies in 28 years (March 2017) and was a co-recipient of the Australian Prime Minister's Prize for Science and in 2018 was elected to the Royal Society (London).
<b>Prof. Dianne Newbury</b> is a molecular geneticist and senior lecturer in the Department of Biological and Medical Sciences at Oxford Brookes University. Her areas of expertise are gene mapping (linkage, association, sequencing), speech and language disorders and neurodevelopmental disorders. Dianne is also a principal investigator of a Research Lab at Oxford Brookes University investigating developmental speech and language disorders underlying speech and language development.
<b>Prof. Michelle Luciano</b> is a Personal Chair of Behavioural Genetics, School of Philosophy, Psychology and Language Sciences, University of Edinburgh, Scotland. Michelle use twin and family modelling to investigate the relative influence of genes and environment on behavior, genome-wide association techniques for gene discovery, plus other analyses to explore the effects of rare and structural genetic variants, gene methylation and biological pathways. She is also interested in the interaction between measured environmental variables with genes.
<b>Prof. Saloni Krishnan</b> is developmental cognitive neuroscientist and professor of cognitive neuroscience at Royal Holloway, University of London where she leads the Neuroscience of Communication Development lab (N-CoDe lab). Her research is focused on identifying how the brains of those with childhood speech and language disorders (such as developmental language disorder, dyslexia, and stuttering) differ from those without these disorders.
<b>Prof. Michael Hildebrand</b> is a molecular geneticist in the Department of Medicine, University of Melbourne, Australia with a well-established track record in applying genetic and functional approaches to elucidate novel pathways involved in human disease. Michael's focus for the past decade has been discovery and characterisation of speech disorder, epilepsy, vascular malformation, and deafness genes.